Lantern Pharma Statistics
Total Valuation
Lantern Pharma has a market cap or net worth of $65.52 million. The enterprise value is $27.36 million.
Market Cap | 65.52M |
Enterprise Value | 27.36M |
Important Dates
The last earnings date was Thursday, May 9, 2024, after market close.
Earnings Date | May 9, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Lantern Pharma has 10.76 million shares outstanding. The number of shares has decreased by -1.05% in one year.
Shares Outstanding | 10.76M |
Shares Change (YoY) | -1.05% |
Shares Change (QoQ) | -0.51% |
Owned by Insiders (%) | 14.75% |
Owned by Institutions (%) | 22.77% |
Float | 7.86M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.83 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.98, with a Debt / Equity ratio of 0.01.
Current Ratio | 9.98 |
Quick Ratio | n/a |
Debt / Equity | 0.01 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -41.20% and return on invested capital (ROIC) is -53.74%.
Return on Equity (ROE) | -41.20% |
Return on Assets (ROA) | -38.40% |
Return on Capital (ROIC) | -53.74% |
Revenue Per Employee | n/a |
Profits Per Employee | -$834,980 |
Employee Count | 21 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +23.06% in the last 52 weeks. The beta is 1.56, so Lantern Pharma's price volatility has been higher than the market average.
Beta (1Y) | 1.56 |
52-Week Price Change | +23.06% |
50-Day Moving Average | 7.12 |
200-Day Moving Average | 4.77 |
Relative Strength Index (RSI) | 47.09 |
Average Volume (30 Days) | 346,633 |
Short Selling Information
The latest short interest is 484,297, so 4.50% of the outstanding shares have been sold short.
Short Interest | 484,297 |
Short Previous Month | 497,300 |
Short % of Shares Out | 4.50% |
Short % of Float | 6.16% |
Short Ratio (days to cover) | 2.23 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -19.32M |
Pretax Income | -17.53M |
Net Income | -17.53M |
EBITDA | -17.36M |
EBIT | -17.53M |
Earnings Per Share (EPS) | -$1.63 |
Balance Sheet
The company has $38.36 million in cash and $193,584 in debt, giving a net cash position of $38.16 million or $3.55 per share.
Cash & Cash Equivalents | 38.36M |
Total Debt | 193,584 |
Net Cash | 38.16M |
Net Cash Per Share | $3.55 |
Equity / Book Value | 35.77M |
Book Value Per Share | 3.32 |
Working Capital | 35.52M |
Cash Flow
In the last 12 months, operating cash flow was -$13.66 million and capital expenditures -$12,075, giving a free cash flow of -$13.67 million.
Operating Cash Flow | -13.66M |
Capital Expenditures | -12,075 |
Free Cash Flow | -13.67M |
FCF Per Share | -$1.27 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Lantern Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | 1.05% |
Shareholder Yield | 1.05% |
Earnings Yield | -26.76% |
FCF Yield | -20.86% |
Analyst Forecast
The average price target for Lantern Pharma is $11.00, which is 82.42% higher than the current price. The consensus rating is "Buy".
Price Target | $11.00 |
Price Target Difference | 82.42% |
Analyst Consensus | Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -12.01% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 3 |